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Abstract 
 
DYRK1A is a dual specificity protein kinase that autophosphorylates a conserved 
tyrosine residue in the activation loop but phosphorylates exogenous substrates only 
at serine or threonine residues. Tyrosine autophosphorylation of DYRK kinases is a 
one-off event that takes place during translation and induces the activation of the 
kinase. Here we characterize the beta-carboline alkaloid harmine as a potent and 
specific inhibitor of DYRK1A both in vitro and in cultured cells. Comparative in vitro-
assays of four kinases of the DYRK family showed that harmine inhibited substrate 
phosphorylation by DYRK1A more potently than the closely related kinase DYRK1B 
(IC50 values of 33 nM vs. 166 nM) and the more distant members of the family, 
DYRK2 and DYRK4 (1.9 µM and 80 µM). Much higher concentrations of harmine 
were required to suppress tyrosine autophosphorylation of the translational 
intermediate of DYRK1A in a bacterial in vitro-translation system (IC50=1.9 µM). 
Importantly, harmine inhibited the phosphorylation of a specific substrate by DYRK1A 
in cultured cells with a similar potency to that observed in vitro (IC50=48 nM), without 
negative effects on the viability of the cells. Overexpression of the DYRK1A gene on 
chromosome 21 has been implicated in the altered neuronal development observed 
in Down syndrome. Here, we show that harmine interferes with neuritogenesis in 
cultured hippocampal neurons. In summary, our data show that harmine inhibits 
DYRK1A substrate phosphorylation with higher potency than tyrosine 
autophosphorylation, and provide evidence for a role of DYRK1A in the regulation of 
neurite formation. 
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 Given its localization on chromosome 21 within the Down syndrome critical 
region and the minimal region for partial monosomy 21, as well as its genetic linkage 
to microcephaly, the human DYRK1A (dual-specificity tyrosine phosphorylation-
regulated kinase 1A) gene has been implicated in the neurodevelopmental 
alterations associated with these syndromes [1,2,3,4]. DYRK1A (also called MNB) is 
the ortholog of the Drosophila mnb (minibrain) gene that is involved in neurogenesis 
[5]. Diverse evidence has also related mammalian DYRK1A to neuronal 
differentiation processes [6,7,8,9,10,11,12,13]. Supporting the pathogenetic role of 
an imbalance in DYRK1A gene dosage, consistent alterations in neurogenesis and 
neuronal structure were observed in mouse models with a selective gain or partial 
loss of function of Dyrk1A (as reviewed in ref. [14]).  
 In addition to its function in neuronal development, recent evidence has also 
implicated DYRK1A in the pathology of neurodegenerative disorders such as 
Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease. DYRK1A 
has been shown to promote the formation of pathophysiological hallmarks of these 
diseases via direct phosphorylation of their most abundant components, such as tau 
in neurofibrillary tangles [11,15,16], α-synuclein in Lewy bodies [17] and amyloid β 
precursor protein (APP) [18]. In addition, we have recently shown that DYRK1A 
phosphorylates septin 4 [19], a protein that has been associated with neurofibrillary 
tangles in Alzheimer’s disease and with α-synuclein-positive cytoplasmic inclusions 
in Parkinson disease. Protein levels, as well as the catalytic activity, of DYRK1A are 
increased in central neurons in Down syndrome and Alzheimer’s disease [11,15,20]. 
These findings raise the possibility that the formation of these protein aggregates in 
neurodegenerative diseases can be prevented or delayed by pharmacological 
inhibition of the excessive activity of DYRK1A. 
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 DYRK1A contains a conserved tyrosine residue in the activation loop of the 
catalytic domain (Tyr321) whose phosphorylation is required for full catalytic activity 
[21]. In contrast to related kinases, such as the MAP-kinase family, the activating 
tyrosine phosphorylation of DYRK family kinases is not catalysed by upstream 
kinases but occurs through autophosphorylation [21,22]. For the Drosophila kinases 
dDYRK2 and MNB, this autophosphorylation has been shown to take place during 
translation [23]. Thus, mature DYRK kinases are incapable of catalyzing their 
tyrosine autophosphorylation [22,24]. This implies that inhibitors of the one-off 
autophosphorylation reaction should irreversibly inhibit DYRK kinases. Lochhead et 
al. [23] have distinguished two classes of DYRK inhibitors, those that target only the 
mature kinase, and those that also inhibit the tyrosine autophosphorylation of the 
translational intermediate. Although purvalanol A has been shown to block tyrosine 
autophosphorylation of dDYRK2 [23], its proposed irreversible effect has not yet 
come under scrutiny. 
 Several compounds originally designed to target other protein kinases also 
inhibit DYRK1A, e.g. the CDK inhibitors roscovitine and purvalanol A [25]. New 
synthetic DYRK1A inhibitors were rationally developed as potential therapeutic 
agents to target learning and memory deficits in Down syndrome, but their selectivity 
has not yet been tested against a broad panel of kinases [26,27]. Two plant 
compounds, epigallocatechin-gallate (EGCG) and harmine, have been identified as 
highly specific DYRK inhibitors in the course of systematic surveys of kinase 
inhibitors [25,28]. EGCG, the major polyphenolic compound of green tea, has been 
used in studies of DYRK1A [24,29], but its usefulness in cell and animal experiments 
is compromised by complicated pharmacokinetic properties and poor bioavailability 
[30,31]. Harmine is an alkaloid originally isolated from the South American vine 
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Banisteriopsis caapi and has previously been characterized as a potent inhibitor of 
monoamine oxidase A (MAO-A) [32].  
 In this study we have determined the potency and specificity of harmine 
towards DYRK1A compared to other members of the DYRK family and analyzed in 
vitro and in cultured cells whether harmine discriminates between substrate 
phosphorylation and tyrosine autophosphorylation of DYRK1A. Finally, we have 
taken advantage of harmine to assess the possible involvement of DYRK1A in 
neurite formation using cultured neurons. 
 
 
 
Results 
 
Harmine inhibits DYRK1A more potently than other members of the DYRK 
family 
 The kinase selectivity screen of Bain and colleagues [28] included DYRK1A, 
DYRK2 and DYRK3 but not DYRK1B or DYRK4. We have therefore compared the 
specificity of harmine towards DYRK1A and related DYRK-kinases in in vitro kinase 
assays and determined the IC50 values for recombinant DYRK1A, DYRK1B, DYRK2, 
DYRK4 and the Drosophila homologue of DYRK1A/DYRK1B, minibrain (MNB). As 
shown in Fig. 1C, harmine inhibited DYRK1A with the highest potency (IC50 value = 
33 nM). Notably, the closely related isoform, DYRK1B (Fig. 1B) was inhibited with 
approximately 5-fold lower potency than DYRK1A (IC50 = 165 nM, see Table 1) and 
approximately similar potency to Drosophila MNB (IC50 = 149 nM, Fig. 1D), which 
also exhibits 85% sequence identity with DYRK1A in the catalytic domain. IC50 values 
for DYRK2 and DYRK4 were found to be more than 10-fold higher (2 µM and 74 µM).  
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The effects of harmine in cell culture 
 We next analyzed the effect of harmine on cell viability, because it has 
previously been characterized as a cytotoxic agent [33]. Viability assays with HeLa 
and HEK293 cells showed that harmine displays minimal toxicity at concentrations up 
to 1 µM (Fig. 2A). Thus, concentrations of harmine that cause near complete 
inhibition of DYRK1A in vitro do not affect cell viability. Similar to the results reported 
by Song et al. [33], toxic effects were observed at harmine concentrations greater 
than 3 µM. Significant reduction of cell viability by high harmine concentrations (10 
µM) was first detectable after 30 h (Fig. 2B). Continuous monitoring of cell growth by 
revealed that inhibitory effects of 3.3 µM and 10 µM harmine were first detectable 
after 12-15 h of treatment (Fig. 2C), consistent with the notion of Song et al. [33] that 
high concentrations of harmine block cell proliferation by inhibiting cyclin dependent 
kinases.  
 To examine whether harmine could inhibit DYRK1A activity in cells, we 
investigated the effect of harmine on the DYRK1A-catalysed phosphorylation of its 
known substrate, the splicing factor SF3B1. We have previously shown that DYRK1A 
phosphorylates SF3B1 at Thr434, and that shRNA-mediated knockdown of DYRK1A 
suppresses the phosphorylation of Thr434 [34]. HeLa cells were transiently 
transfected with an expression vector encoding a fusion protein of green fluorescent 
protein (GFP) and the N-terminal part of SF3B1 (amino acids 1-492) and treated with 
varying concentrations of harmine. Western blot analysis showed that harmine 
reduced the level of phospho-Thr434 in SF3B1 in a concentration-dependent manner 
(Fig. 3A). Quantitative evaluation of three independent experiments yielded an IC50 
value of 48 nM (Fig. 3B). This experiment shows that harmine is a highly cell-
permeant inhibitor of DYRK1A.  
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Harmine does not inhibit tyrosine autophosphorylation of DYRK1A in HEK293 
cells 
 Next, we asked whether harmine could not only inhibit the activity of the 
mature form of DYRK1A (as in the in vitro assays), but also prevent its activation by 
tyrosine autophosphorylation. To address this question, we used a HEK293 subline 
that overexpresses GFP-DYRK1A stably under the control of a doxycyclin-
regulatable promoter [19]. Immediately after induction with doxycyclin, the cells were 
(or were not) treated with harmine for 48 h. GFP-DYRK1A was immunoprecipitated 
and subjected to kinase assays and Western blot analysis (Fig. 4). Harmine was 
applied at a concentration of 4 µM, at which concentration the phosphorylation of 
Thr434 in the endogenous SF3B1 in HEK293 cells was completely blocked (Fig. 4B). 
In contrast, harmine treatment only modestly inhibited tyrosine phosphorylation of 
GFP-DYRK1A (Fig. 4A). Furthermore, the catalytic activity of GFP-DYRK1A that was 
isolated from harmine treated cells did not differ significantly (p = 0.09) from that 
purified from untreated cells (Fig. 4C). This result indicates that harmine does not 
inhibit the activation of DYRK1A by tyrosine autophosphorylation at a concentration 
that leads to the complete inhibition of DYRK1A activity towards SF3B1.  
 
The effect of harmine on tyrosine autophosphorylation in vitro 
 Lochhead et al. [23] had employed a cell free translation system based on 
rabbit reticulocyte lysates to determine the differential effects of inhibitors on tyrosine 
autophosphorylation of Drosophila DYRK2. Our attempts to reproduce this result for 
mouse DYRK1A failed, probably because the amounts of in vitro-translated protein 
were too small for the immunochemical detection of phosphotyrosine (data not 
shown). Much higher amounts of FLAG-DYRK1A were produced when we used 
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wheat germ extract for the in vitro-translation, allowing us to determine the 
phosphotyrosine content by Western blot analysis (Fig. 5A). Harmine was applied at 
a concentration of 1 µM, which inhibited the catalytic activity of DYRK1A by more 
than 90%, both in vitro (Fig. 1) and in HeLa cells (Fig. 3). It was also applied at 10 µM 
to achieve maximal inhibition. For comparison, the effect of purvalanol A was 
analyzed in parallel because this inhibitor was shown by Lochhead et al. [23] to 
inhibit the tyrosine autophosphorylation of Drosophila DYRK2 at a concentration of 
50 µM. Both harmine and purvalanol A caused a reduction of immunoreactive 
phosphotyrosine in FLAG-DYRK1A, although tyrosine autophosphorylation was only 
partially blocked even at the higher concentrations of the inhibitors (Fig. 5B). The 
catalytic activity of FLAG-DYRK1A after purification from the reaction mixture was 
unaffected by the preceding treatment with harmine and it was marginally reduced 
after treatment with purvalanol A (Fig. 5C).   
 
In vitro translation in a bacterial expression system 
 In vitro translation in eukaryotic cell-free systems allowed us to study the effect 
of harmine on the co-translational tyrosine autophosphorylation of the DYRK kinases. 
However, such reaction mixes are still highly complex systems containing other 
protein kinases and proteins that may indirectly affect the enzymatic properties of 
DYRK1A. Therefore, we took advantage of the newly developed PURExpress in 
vitro-translation system, which relies on well-defined and purified components from E. 
coli to reconstitute cell-free translation [35]. For these experiments, we generated a 
bacterial expression construct that produced only the catalytic domain of DYRK1A 
(DYRK1Acat), and thus lacked most of the tyrosines in the N-terminal domain. In 
particular, DYRK1Acat does not include Tyr111, which we have previously identified 
as a major autophosphorylation site of recombinant DYRK1A in E. coli [21]. First, we 
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determined the time course of DYRK1Acat tyrosine autophosphorylation. 
Recombinant His6-SF3B1-NT was added as a substrate for DYRK1A in order to 
assess whether catalytically active DYRK1Acat was produced by the bacterial in 
vitro-translation system. As shown in Fig. 6A, pThr434 phosphorylation was 
detectable after 30 min, whereas no phosphorylation of SF3B1 took place in control 
reactions expressing dihydrofolate reductase (data not shown). Tyrosine 
phosphorylation of DYRK1Acat was first detectable after 60 min and increased 
further over time. These results confirm that the DYRK1Acat construct generated by 
the cell-free bacterial expression system is capable both of tyrosine 
autophosphorylation and substrate phosphorylation much like the native protein. The 
fact that substrate phosphorylation was detected prior to autophosphorylation may be 
attributable to the differing sensitivities of the phospho-specific antibodies. Next, we 
added harmine to the in-vitro transcription/translation reaction in order to analyze its 
effect on tyrosine autophosphorylation. As shown in Fig. 6B, harmine concentration-
dependently inhibited the tyrosine autophosphorylation of DYRK1Acat with an IC50 of 
1.80 µM.  
 
The effect of harmine on neurite formation in hippocampal neurons  
 To assess the physiological consequences of the inhibition of the protein 
kinase activity of DYRK1A by harmine in the nervous system, we set out to test its 
effects on neuronal differentiation, a complex sequence of processes in which MNB 
and DYRK1A have been previously implicated (see Introduction). Several 
observations point to a role of DYRK1A in neuritogenesis, an early differentiation 
process, although no direct evidence has been so far provided (see Discussion for 
details). Accordingly, we decided to use harmine to assess this new possible function 
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of DYRK1A. Thus, we focus our analysis on the effects of harmine on neurite 
formation using cultured hippocampal neurons prepared from mouse embryos. 
 First, we tested the consequences of harmine treatment on the viability of 
these cells. In agreement with what we found in the cell lines, we did not detect any 
apparent negative effect within 5 days of culture at concentrations up to 2 µM (not 
shown). In order to ensure that only stably growing neurites but not transient filopodia 
were considered in our analysis, cells were fixed in cold paraformaldehyde and their 
morphology (i.e. number of growing neurites) was analyzed by anti-β3 tubulin (TUJ1) 
antiserum immunostaining. As shown in Fig. 7A, hippocampal neurons that were 
treated with harmine for 3 days at a concentration of 1.6 µM displayed a significant 
reduction in the number of neurites compared to untreated controls. For instance, 
harmine shifted the median number of neurites of these neurons from four to three 
(Fig. 8A, B, C). This overall decrease in the number of neurites was statistically 
significant as determined by a paired Student´s t test of the mean value of the 
number of neurites per neuron from three independent experiments (p=0.021). 
Nevertheless, we noticed that the inhibitory effect of harmine was statistically 
significant only for neurons with 4 or less neurites when data of control and harmine-
treated neurons were paired for independent Student´s t test analysis (Fig. 8A). This 
may suggest that harmine was less effective in neurons that were already developing 
neurites at the time when harmine was added to the culture. 
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Discussion 
In this study we have determined the inhibitory potency of the β-carboline 
alkaloid harmine towards DYRK1A and the closely related kinases DYRK1B, DYRK2 
DYRK4 and Drosophila MNB. Furthermore, we demonstrate that harmine 
differentially inhibits substrate phosphorylation by the mature DYRK1A protein and 
tyrosine autophosphorylation of the translational intermediate of DYRK1A. Finally, we 
take advantage of harmine to provide evidence for a function of DYRK1A in neurite 
formation. 
Specificity is a serious concern whenever inhibitors are used to dissect the 
biological functions of a given protein kinase, as unwanted effects on other kinases 
may lead to erroneous conclusions. Here we show that harmine displays exceptional 
specificity towards DYRK1A even in comparison with the other members of the 
DYRK family. The IC50-value for DYRK2 (2 µM) was about 50-fold higher than for 
DYRK1A (33 nM), whereas DYRK4 was largely resistant to harmine (IC50 > 50 µM). 
Our result for DYRK2 matches quite well with the published data of Bain et al. [28] 
who measured IC50 values of 0.9 µM (at 50 µM ATP) for DYRK2 and 0.8 µM for its 
closest neighbor, DYRK3. Five-fold higher concentrations of harmine were required 
for the inhibition of DYRK1B or MNB than for DYRK1A (Table 1), although these 
kinases exhibit 85% sequence identity with DYRK1A in the catalytic domain.  
 Although important, this difference between the inhibitory potencies of harmine 
towards DYRK1A and DYRK1B is too small to fully discriminate pharmacologically 
between the cellular effects of these kinases. Nevertheless, at a concentration of 1 
µM, harmine inhibits DYRK1A, DYRK1B by >90% but only marginally affects the 
activities of other DYRK family members. Side effects caused by inhibition of other 
protein kinases are unlikely because Bain et al. [28] reported modest inhibition by 
harmine only for CK1 (IC50 = 1.5 µM) and PIM3 (IC50 = 4.3µM), among 69 kinases 
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tested. Actually, harmine has been applied at concentrations of 1 µM in recent 
studies to confirm the proposed role of DYRK1A in the phosphorylation of caspase 9 
[36,37] and septin 4 [19] and in the negative regulation of NFAT signaling in 
cardiomyocytes [38].  
We measured an IC50 of 33 nM for the inhibition of DYRK1A by harmine in 
vitro, which is in reasonable agreement with the value obtained by Bain et al. [28] (80 
nM). This is an exceptionally high potency for a low molecular weight compound (212 
Da) that has not been optimized for its affinity. Importantly, harmine inhibited 
endogenous DYRK1A in HeLa cells with a similarly high potency (IC50 = 48 nM), 
which is prerequisite for use of the inhibitor in cell culture experiments. However, 
harmine inhibits monoamine oxidase A with an IC50 of 5 nM [32], which precludes the 
inhibition of DYRK1A in animal experiments without simultaneously blocking MAO-A. 
On the other hand, the antidiabetic effect of harmine as an inducer of PPARγ 
expression required concentrations higher than 1 µM [39]. Hence, this effect of 
harmine is necessarily accompanied by a near-maximal inhibition of DYRK1A. 
Interestingly, mean peak plasma levels of 0.54 µM harmine have been determined in 
volunteers after ingestion of the hallucinogenic hoasca beverage within a ceremonial 
context [40]. Hoasca is a decoction of Banisteriopsis caapi and dimethyltryptamine-
containing plants, and is regularly used in shamanic rituals and South American sects 
for its visionary effects. Thus, regular users of hoasca are repeatedly exposed to 
levels of harmine that cause a substantial inhibition of DYRK1A. Similar doses of 
harmine to those ingested by hoasca users (about 250 mg, [40] were used at the end 
of the 1920s for the treatment of postencephalitic Parkinsonism [41].  
 A point of particular interest to note in respect of the inhibitors of DYRK 
kinases is the potential capacity to block autophosphorylation of the critical activation-
loop tyrosine, which is expected to irreversibly inhibit the kinase [23]. We found no 
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reduction of phosphotyrosine in GFP-DYRK1A that was isolated from harmine-
treated HEK293 cells, and the catalytic activity was unaltered when compared to 
GFP-DYRK1A from untreated cells (Fig. 4). In the same cells, phosphorylation of 
SF3B1 at Thr434 was completely blocked by treatment with harmine. Of note, 
DYRK1A autophosphorylation at Ser520 in HEK293 cells was almost completely 
inhibited by harmine treatment at a concentration of 1 µM [36]. Taken together, these 
results indicate that harmine inhibits both substrate phosphorylation and serine 
autophosphorylation of mature DYRK1A but not tyrosine autophosphorylation of the 
translational intermediate.  
 The in vitro-translation of DYRK1A in wheat germ extract allowed us to test 
higher concentrations of harmine (10 µM) that are toxic for cells. The presence of 
harmine during translation caused a concentration-dependent inhibition of tyrosine 
autophosphorylation of DYRK1A, although the inhibitory effect did not reach 
statistical significance and was much less potent than the inhibition of substrate 
phosphorylation. In contrast to our results, Seifert et al. [37] reported a concentration-
dependent reduction of immunoreactive phosphotyrosine of in vitro-translated 
DYRK1A with complete inhibition at 1 µM harmine. These seemingly divergent 
results may be attributable to the different in vitro-translation systems used (wheat 
germ extract vs. rabbit reticulocyte lysate), different concentrations of ATP used in 
the reactions, or the use of different phosphotyrosine-specific antibodies. Different 
monoclonal antibodies may recognize different phosphotyrosine residues, and the 
Phosphosite database (www.phosphosite.org) lists seven phosphorylated tyrosine 
residues for DYRK1A, most of which are localized in the N-terminal domain.  
 We consider the results obtained with the PURExpress system to be the most 
informative concerning the inhibitory effect of harmine on tyrosine 
autophosphorylation. This translation system is reconstituted from isolated E. coli 
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ribosomes and purified recombinant proteins (including aminoacyl-tRNA synthetases, 
translation initiation, elongation and release factors) and is not prone to the effects of 
undefined proteins in the reaction [35]. Notably, tyrosine autophosphorylation of 
DYRK1Acat in this system demonstrates that this reaction is an intrinsic capacity of 
the catalytic domain of DYRK1A and does not require the presence of molecular 
chaperones. About 50-fold higher concentrations of harmine were required to inhibit 
the tyrosine autophosphorylation of the translational intermediate DYRK1A (IC50 = 
1.8 µM) than the phosphorylation of DYRKtide by the mature DYRK1A (IC50 = 0.033 
µM). This quantitative analysis confirms and refines the qualitative finding that 
tyrosine autophosphorylation of DYRK kinases differs from the canonical substrate 
phosphorylation in the sensitivity to small-molecule inhibitors [23].  
 Lochhead et al. [23] identified purvalanol A as the paradigmatic inhibitor of 
cotranslational tyrosine autophosphorylation of Drosophila dDYRK2, using rabbit 
reticulocyte lysate. Although no quantitative evaluation was provided, the published 
data suggest that purvalanol A inhibited the phosphorylation of a peptide substrate by 
dDYRK2 with a similar IC50 as for the tyrosine autophosphorylation. In contrast, 50 
µM purvalanol A only partially blocked tyrosine autophosphorylation of mouse 
DYRK1A (Fig. 5B), though purvalanol A inhibited the in vitro-phosphorylation of 
DYRKtide by DYRK1A with an IC50 of 300 nM (data not shown). The differential 
sensitivity of mammalian DYRK1A and dDYRK2 (the ortholog of mammalian DYRK4) 
to purvalanol A is not surprising, given that these kinases belong to distinct branches 
of the DYRK family of protein kinases (Fig. 1B).  
 Extensive evidence relates mammalian DYRK1A and its orthologues 
(Drosophila MNB, chicken MNB) to neuronal differentiation processes. In particular, 
the fact the MNB/DYRK1A is localized in the growing dendritic tree of diverse 
vertebrate central neurons [7,12] strongly suggests a role in the regulation of dendrite 
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growth. This function is supported by evidence that cortical pyramidal neurons of 
Dyrk1A+/- mouse exhibit smaller dendritic arbors than those of wild type mice [8] and 
conversely, hippocampal and cortical neurons of transgenic mice that overexpress 
Dyrk1A exhibit increased size [42]. Nevertheless, there are also some indications that 
MNB/DYRK1A might be involved in earlier steps of neuronal differentiation. For 
instance, upregulation of MNB/DYRK1A expression has been shown to precede the 
onset of dendrite formation in several neuronal populations [7,12]. It has also been 
reported that DYRK1A is markedly upregulated during the bFGF-induced 
differentiation of a hippocampal progenitor cell line and that blockade of this 
upregulation significantly inhibits neurite formation [6]. Moreover, a recent RNAi 
screen in Drosophila identified MNB as a regulator of cell protrusions in cell lines 
derived from the central nervous system [43]. Together, these data point to the 
possible involvement of DYRK1A on the regulation of neurite formation. Accordingly, 
we have here shown that harmine inhibited neuritogenesis in cultured hippocampal 
neurons. Thus, our results provide the first evidence for a role of DYRK1A on neurite 
formation in bona fide neurons. Future research should shed light upon the molecular 
mechanisms underlying this novel DYRK1A function. 
 In conclusion, the present data show that harmine is a potent and selective 
inhibitor that can be used as a pharmacological tool to interfere with functions of the 
protein kinase DYRK1A in cultured neurons. Although the exploration of its 
therapeutic options using Down syndrome animal models are in principle 
compromised by its MAO inhibitory effect, harmine may serve as a lead compound to 
develop a novel DYRK1A inhibitor devoid of MAO inhibiting activity. 
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Materials and Methods 
 
Cell culture and transfection 
HeLa cells were cultured in RPMI-1640 medium (PAA Laboratories, Pasching, 
Austria) supplemented with 10% fetal calf serum (PAA) at 37°C in a humidified 5% 
CO2 atmosphere. For controlled overexpression of DYRK1A, we used a stably 
transfected HEK293 cell clone expressing GFP-DYRK1A under the control of a 
tetracycline-regulated promoter (HEK-tetGFP-DYRK1A) [19]. HEK293 cells were 
maintained in DMEM High Glucose (4.5 mg/l) (PAA) supplemented with 10% fetal 
calf serum. Expression of GFP-DYRK1A was induced with 2 µg/ml doxycycline.  
 
Inhibitors 
Harmine (No. 51400, Fluka, Buchs, Switzerland) was dissolved in ethanol under 
constant agitation at room temperature to generate a 10 mM solution which was then 
diluted to a concentration of 0.5 mM with 50% (v/v) ethanol. This stock solution was 
further diluted to the working concentrations with water for in vitro-experiments or 
with culture medium for the treatment of cultured cells. Purvalanol A (Alexis 
Biochemicals, Lausen, Switzerland) was dissolved in DMSO to produce a 30 mM 
solution. Further dilutions for in vitro experiments were also made in DMSO.  
 
Antibodies 
The rabbit antibody for the specific detection of phosphorylated Thr434 in SF3B1 
(pThr434) has been described previously [34]. Sheep anti-DYRK1A antibody raised 
against bacterially expressed GST-DYRK1A-∆C was kindly provided by Philip Cohen 
(MRC Protein Phosphorylation Unit, Dundee, Scotland, UK). The following antibodies 
were purchased from commercial sources: mouse monoclonal pan-specific 
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SF3B1/SAP155 antibody (MBL, Nagoya, Japan) and anti phosphotyrosine antibody 
(PY99, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-DYRK1A (Cell 
Signaling Technology, Beverley, MA) and anti-GFP-antibody (Molecular Probes, 
Eugene, OR; for immunoprecipitation), and goat GFP-specific antibody (Rockland, 
Gilbertsville, PA) for immunodetection on Western blots) 
 
Bacterial expression of recombinant proteins  
Plasmids for the bacterial expression of glutathione S-transferase-(GST-)DYRK1A-
∆C, GST-DYRK1B-p69, and GST-DYRK2 have been described previously [21,44,45] 
(UniProt acc. Nos. Q63470, Q9Y463, Q92630). The Drosophila minibrain kinase 
(MNB)(P49657) was expressed as a fusion protein with maltose binding protein (MBP) 
[45]. GST and MBP fusion proteins were expressed in E. coli and affinity purified 
using glutathione Sepharose 4B (Amersham Bioscience, Piscataway, NJ) or amylose 
agarose (New England Biolabs, Beverley, MA). GST-DYRK4 (Q9NR20) expressed 
from insect cells was obtained commercially (lot 37361G, Invitrogen, Carlsbad, CA). 
For all DYRK kinases, one unit of kinase activity was defined as the amount of 
enzyme that catalyzed the phosphorylation of 1 nmol DYRKtide per min at 30°C. 
His6-tagged SF3B1-NT was prepared as described previously [34]. 
 
In vitro protein kinase assays 
Assays were performed in reaction mixtures of 12 µl at 30°C with 8 to 10 different 
harmine concentrations. Recombinant kinases were added at sufficient 
concentrations to obtain activities between 0.4 to 5 mU per 12 µl. The reaction was 
incubated with 100 µM ATP, 100 µM DYRKtide, and 0.6 µCi [γ-³³P]-ATP in kinase 
buffer (25 mM Hepes, pH 7.0, 5 mM MgCl2, 0.5 mM dithiothreitol) for 5 min at 30°C. 
The incorporation of ³³P into DYRKtide was determined in triplicate by dotting 3 µl-
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aliquots of the reaction mixture onto 0.5x3.0 cm pieces of phosphocellulose P-81 
(Whatman, Maidstone, UK), followed by washing in 5% phosphoric acid (10 times for 
10 minutes each time), and subsequent liquid scintillation counting.  
 
Viability assay 
Effects of inhibitors on cell proliferation and viability were determined with a 
tetrazolium salt-based assay (WST-1, Quick Cell Proliferation Assay Kit, Biovision, 
Mountain View, CA). HeLa or HEK293 cells were seeded at a density of 5000 
cells/well on 96-well plates. After overnight culture, serial dilutions of harmine in 
culture medium were applied to the wells (as triplicate samples) and the cells were 
cultured for 56 h without changing the medium, before the WST-1 assay was 
performed in accordance with the manufacturer’s instructions. In the time course 
experiment, harmine was added 10 h, 30 h or 54 h before addition of WST-1.  
 
Real-time cell-electrode impedance measurements  
We used the xCELLigence System (Roche Diagnostics, Penzberg, Germany) for 
real-time monitoring of harmine cytotoxicity. Two hundred microliters of growth 
medium were added to the wells of an E-plate for background measurements. HeLa 
cells were seeded in triplicate wells at a number of 3,000 and 5,000 cells/well in 200 
µl. After 24 hours, 100 µl of the medium was removed, harmine was added to the 
respective wells in a volume of 100 µl of fresh medium The continuous impedance 
measurement was recorded and converted to a cell index. Results were analyzed 
using RTCA Software 1.1 (Roche Diagnostics).  
 
Assay of SF3B1 phosphorylation by DYRK1A in HeLa cells 
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HeLa cells were seeded at 80,000 cells/well in 6-well culture plates. After overnight 
culture, the cells were transfected with the pEGFP-SF3B1-NT plasmid (0.5 µg 
DNA/well, [34] using the transfection reagent FuGENE 6 (Roche Molecular 
Biochemicals, Mannheim, Germany). Two hours after transfection, the cells were 
treated with harmine at variable concentrations (0.01-1 µM). Two days after 
transfection, the cells were lysed with 150 µl boiling SDS-buffer (20 mM Tris, pH 7.4; 
1% SDS), denatured for 5 minutes at 96°C and sonicated for 30 s. The 
phosphorylation of Thr434 was assessed by Western blot analysis using a rabbit 
antibody specific for phosphorylated Thr434 in SF3B1 (pThr434) [34]. The Western 
blots were developed using horseradish peroxidase-coupled secondary antibodies 
and chemiluminescence detection. The immunoreactivity was quantitated with a LAS-
3000 CCD imaging system and the AIDA Image Analyzer 5.0 program (Raytest, 
Straubenhardt, Germany). The values were normalized to GFP-SF3B1-NT 
expression levels as determined with a pan-specific antibody (anti-SF3B1/SAP155).  
 
Harmine treatment of cultured hippocampal neurons 
Cultures of embryonic mouse hippocampal cells were prepared following standard 
protocols [46]. In brief, hippocampi from E18 mouse embryos were finely dissected in 
Hank’s Balanced Salt Solution (HBSS). After a mild and short incubation with trypsin 
in HBSS, the cells were dispersed in DMEM (Invitrogen) medium supplemented with 
10% fetal bovine serum and antibiotics (penicillin and streptomycin). After counting 
and a viability test employing trypan blue, the cells were plated on poly-L-lysine 
coated 12 mm coverslips at a density of 25,000 viable cells/cm2. After 3h, non-
attached cells were removed by washing and the media was changed to Neurobasal 
medium (Invitrogen) supplemented with 2% B27, 2 mM Glutamax plus antibiotics in 
the presence or absence of harmine. The cells were grown for 3 days in 24-well 
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plates. After a brief wash with PBS, the cells were fixed with cold 4% 
paraformaldehyde in PBS for 1 h and washed with PBS. Immunocytochemical 
staining of the cells was carried out following standard protocols using anti-β3 tubulin 
antiserum (TUJ1, Covance) followed by biotinylated anti-Mouse IgG secondary 
antiserum and streptavidin-coupled horseradish peroxidase (ABC kit, Vector labs, 
Burlingame, CA). The cells were observed under the microscope and the number of 
neurites were counted for a minimum of 100 isolated cells per coverslip. The criteria 
for a neurite to be counted were to be labelled with TUJ1, to be longer than 
approximately 10 µm, and to have a growth cone. 
 
Immunocomplex kinase assay of GFP-DYRK1A and analysis of tyrosine 
phosphorylation 
HEK-tetGFP-DYRK1A cells were seeded onto 10-cm plates. Two hours after 
seeding, expression of GFP-DYRK1A was induced by adding 2 µM doxycycline, and 
the cells were then treated with 0.5-4 µM harmine. Two days later, cells were lysed 
under non-denaturating conditions using 1 ml of native lysis buffer per plate (50 mM 
Hepes pH 7.4, 150 mM NaCl, 25 mM NaF, 2 mM EDTA, 30 mM sodium 
pyrophosphate, 0.5% Igepal CA-630 (Sigma), 1 mM sodium vanadate, 10 µg/ml 
pepstatin, 10 µg/ml leupeptin, 1 mM PMSF, 10 µg/ml aprotinin) on ice. The samples 
were spun down for 5 minutes, and 18 µl aliquots of the supernatants were taken 
separately for Western blot analysis. The remaining supernatants were incubated 
with 2 µl of rabbit anti-GFP-antibody (Molecular Probes, Eugene, OR) at 4°C for one 
hour before the immuncomplexes were captured using EZview Red Protein G Affinity 
Gel (Sigma) at 4°C over-night.  
After washing the agarose beads twice with washing buffer containing Igepal CA-630 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.1% Igepal), twice with 
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washing buffer without Igepal and once with kinase buffer, GFP-DYRK1A was 
assayed in vitro for kinase activity. The assays were carried out at 30°C for 30 min in 
a total reaction volume of 30 µl as described above, except that here we used a 
concentration of 10 µM ATP. After washing the immunoprecipitates with Igepal-free 
washing buffer, the bound proteins were eluted with sample buffer, separated by 
SDS-PAGE (8%) and blotted onto nitrocellulose membranes. The membranes were 
subjected to Western blot analysis as indicated in the figure legends. 
 
In vitro translation of DYRK1A 
An expression plasmid for FLAG-tagged mouse DYRK1A with a T3 promotor 
sequence upstream of the open reading frame (pCMV-Tag2A-FLAG-DYRK1A) was 
kindly provided by Beat Lutz (Johannes Gutenberg Universität Mainz, Germany). 
Capped mRNA was obtained by in vitro transcription of 1 µg of the linearised plasmid 
(KspAI) using the mMESSAGE mMACHINE High Yield Capped RNA transcription kit 
(Ambion, Darmstadt, Germany).  
 In vitro translations with Wheat Germ Extract Plus (Promega) were performed 
according to the manufacturer’s instructions in total reaction volumes of 50 µl, using 
2 µg of RNA and 1 µl of the inhibitor. After incubation for 2 h at 25°C, 500 µl of the 
lysis buffer was added to stop the reaction. The samples were immunoprecipitated 
overnight with 20 µl of anti-FLAG M1 agarose affinity resin (Sigma, Taufkirchen, 
Germany) at 4°C and analysed by immunocomplex kinase assay and Western blot 
analysis. The kinase activities were normalised to the amount of FLAG-DYRK1A as 
determined via Western blotting.  
 The PURExpress kit (New England Biolabs, Ipswich, MA) was employed for 
coupled in vitro transcription/translation experiments in an E. coli-derived system. For 
these experiments we constructed an expression vector, pET28a-DYRK1Acat, to 
Page 21 of 38 FEBS Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 22 
produce a deletion construct of rat DYRK1A that lacks both the non-catalytic N- and 
C-terminal domains of DYRK1A (bases 532-1626 of X79769, encoding amino acids 
135 – 499 of DYRK1A). For the time course (Fig. 6A), a 35-µl reaction containing 350 
ng of pET28a-DYRK1Acat was supplemented with 2.3 µg SF3B1-NT-His6 [31](de 
Graaf et al., 2006) as a substrate for DYRK1A and 4 µl aliquots were taken and 
stopped by the addition of EDTA at different time points. To test the effect of harmine, 
reaction mixes (with final volumes of 8 µl) contained 10 ng/µl of the expression 
plasmid and were incubated for 2 h at 30°C unless otherwise indicated. After addition 
of gel loading buffer, the samples were incubated at 96°C for 5 min and Western 
blotted.  
 
Analysis of quantitative data 
The GraphPad Prism 5.0 program (GraphPad Software, La Jolla, CA) was used for 
curve fitting by nonlinear regression and statistical analysis. The data generated in in 
vitro kinase assays were fitted to a one-site inhibition model (to a “dose-response 
curve – inhibition”) with a Hill slope of -1 or a variable Hill slope (Y=100/(1+10^((X-
LogIC50))); or for variable slope: Y=100/(1+10^((LogIC50-X)*HillSlope))) ). For each 
data set, the model with the best fit was determined with the extra sum of squares F 
test (p<0.05). For quantitative evaluation of the HeLa cell experiment (Fig. 3), band 
intensities were fitted to a “dose-response curve - inhibition” with a Hill slope of -1. 
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Figure Legends  
 
Fig. 1. Inhibition of DYRK family kinases by harmine. 
A, The structure of harmine 
B, The relationship of mammalian DYRK kinases according to the sequence 
similarity in the catalytic domain. Percent values indicate the sequence identity 
between different family members.  
C and D, Recombinant kinases were incubated with the substrate peptide DYRKtide 
in the presence of different harmine concentrations and 100 µM ATP. The data were 
analyzed using the GraphPad Prism 5 program and fitted to a “dose-response curve 
– inhibition” with a Hill slope of -1 or a variable slope if the Hill slope was significantly 
different from –1 (Table 1). Results are presented as means +/- SEM, (n=3-5 or n=2-
4 for DYRK4). 
 
Fig. 2. Cytotoxicity of harmine. 
A, Concentration-response curves. - Proliferating HEK293 cells or HeLa cells were 
incubated with variable concentrations of harmine for 56 h. Cell viability was 
determined as the capacity of the cells to reduce WST-1 and normalized to that of 
untreated cells. The graphs summarize the results of three independent experiments 
(means +/- SEM). 
B, Time course. - HeLa cells were treated for variable times with the indicated 
concentrations of harmine before the WST-1 reagent was added. 
C, Real-time monitoring of harmine cytotoxicity.-  Impedance measurement for 
determination of cell growth were converted to a cell index and normalized to the time 
point where harmine was added. Curves represent means of triplicate wells. In order 
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to present the results more clearly, error bars for the S.D. are not shown for time 
points < 20 h.  
 
Fig. 3. Harmine inhibits SF3B1 phosphorylation by DYRK1A in HeLa cells. 
HeLa cells were transfected with pEGFP-SF3B1-NT plasmids and treated with 
harmine for 48 hours. Two days after transfection, phosphorylation of SF3B1 was 
determined by immunoblotting with an anti-pThr434 antibody, and the results were 
normalized to the total amount of SF3B1 immunoreactivity.  
A, Representative Western blot.  
B, Quantitative evaluation. The diagram presents the results of three independent 
experiments as the means of normalized pThr434 immunoreactivity relative to that in 
untreated cells +/- SEM. 
 
Fig. 4. Harmine does not inhibit tyrosine autophosphorylation of DYRK1A in HEK293 
cells 
A, HEK293-GFP-DYRK1A cells were stimulated with doxycycline  and treated with 
harmine as indicated. Native lysates were subjected to immunoprecipitation with anti 
GFP antibody. DYRK1A phosphorylation was analyzed by immunoblotting with a 
phosphotyrosine-specific antibody (P-Tyr). The left panel shows Western blots of a 
representative experiment, while the right panel shows the quantitative evaluation of 
3 experiments (means +/- SEM). The signal intensities of P-Tyr immunoreactivity 
were normalised to the anti GFP signal. The difference between the control and the 
harmine treated groups was not statistically significant (Student’s t test, p=0.09). 
B, Aliquots of the cell lysates were analyzed for phosphorylation of endogenous 
SF3B1 at Thr434 to confirm the efficacy of the harmine treatment. 
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C, Kinase activity of precipitated GFP-DYRK1A was determined by in vitro assays 
with DYRKtide and normalized to GFP immunoreactivity. The difference in activity 
between DYRK1A from the control and the harmine treated cells was not statistically 
significant (Student’s t test, p=0.09). Columns and error bars represent means +/- 
SEM from 3 experiments.  
 
Fig. 5. In vitro translation of DYRK1A in wheat germ extract 
FLAG-DYRK1A was translated in wheat germ extract in the presence of different 
concentrations of harmine or purvalanol A as indicated. The translated kinase was 
immunoprecipitated with anti-FLAG antibody and subjected to Western blot analysis 
with a phosphotyrosine-specific antibody (P-Tyr). Panel A shows Western blots from 
a representative experiment. Panel B shows the quantitative evaluation of 3 
experiments (means +/- SEM). Signal intensities of phosphotyrosine 
immunoreactivity were normalized to the anti-DYRK1A signal. Panel C shows the 
kinase activity of precipitated kinase as determined by in vitro assay with DYRKtide. 
The activities were normalized to DYRK1A immunoreactivity. 
 
Fig. 6. Effect of harmine on DYRK1A tyrosine autophosphorylation in an E. coli-
derived in vitro-translation system.   
A, DYRK1Acat was transcribed and translated in a reconstituted E. coli system in the 
presence of recombinant SF3B1-NT. Aliquots of the reaction mixture were taken at 
the times indicated and subjected to Western blot analysis. SF3B1-NT was gradually 
degraded during course of the experiment. The band labelled by the asterisk (*) is 
probably a transient degradation product of SF3B1. The hash key (#) marks an 
unidentified band.   
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B, DYRK1Acat was in vitro translated in the presence of the indicated concentrations 
of harmine. The reactions were run for 2 h before the immunoblot analysis. Western 
blots of a representative experiment are shown in the upper panels. For quantitative 
evaluation, the signal intensities of phosphotyrosine immunoreactivity were 
normalized to the anti DYRK1A signal. The graph summarizes the data from three 
independent experiments (means +/- S.D.). The data were analyzed by nonlinear 
curve fitting (IC50 = 1.80 µM, 95% confidence interval 0.34-9.62 µM).   
 
Fig. 7. Effect of harmine on neurite formation in hippocampal neurons. 
Hippocampal neurons were cultured for three days in the presence or absence 
(control) of 1.6 µM harmine. A, Graphical representation of the data of three 
independent experiments. No neurons were found with less than two or more than six 
neurites. The columns represent means ± S.D. from three independent experiments. 
Student´s t test analysis was applied to each pair of control and harmine treated data. 
B,C, Images of representative neurons immunostained with anti-β3 tubulin antiserum 
from control and harmine treated cultures, exhibiting four and three neurites, 
respectively.  
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Tables 
 
Table 1 Quantitative analysis of the data presented in Fig. 1 
a, significantly different from -1 (extra sum of squares F test, p<0.05) 
 
 
Kinase IC50 [nM] 95% confidence interval, IC50 [nM] 
Goodness of fit 
(R²) Hill slope 
DYRK1A 33 26-42 0.977 -0.662a 
DYRK1B 166 133-205 0.970 -1 
MNB 149 128-175 0.982 -1 
DYRK2 1,931 1,197-3,115 0.881 -1 
DYRK4 79,750 39,780-159,900 0.842 -0.405a 
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